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RESEARCH ARTICLE
Antibody responses to P. falciparum 
blood stage antigens and incidence of clinical 
malaria in children living in endemic area 
in Burkina Faso
Mariama K. Cherif1,2, Oumarou Ouédraogo1,3, Guillaume S. Sanou1, Amidou Diarra1, Alphonse Ouédraogo1, 
Alfred Tiono1, David R. Cavanagh4, Theisen Michael5, Amadou T. Konaté1, Nora L. Watson6, Megan Sanza6, 
Tina J. T. Dube6, Sodiomon B. Sirima1 and Issa Nebié1*
Abstract 
Background: High parasite-specific antibody levels are generally associated with low susceptibility to Plasmodium 
falciparum malaria. This has been supported by several studies in which clinical malaria cases of P. falciparum malaria 
were reported to be associated with low antibody avidities. This study was conducted to evaluate the role of age, 
malaria transmission intensity and incidence of clinical malaria in the induction of protective humoral immune 
response against P. falciparum malaria in children living in Burkina Faso.
Methods: We combined levels of IgG and IgG subclasses responses to P. falciparum antigens: Merozoite Surface Pro-
tein 3 (MSP3), Merozoite Surface Protein 2a (MSP2a), Merozoite Surface Protein 2b (MSP2b), Glutamate Rich Protein R0 
(GLURP R0) and Glutamate Rich Protein R2 (GLURP R2) in plasma samples from 325 children under five (05) years with 
age, malaria transmission season and malaria incidence.
Results: We notice higher prevalence of P. falciparum infection in low transmission season compared to high malaria 
transmission season. While, parasite density was lower in low transmission than high transmission season. IgG against 
all antigens investigated increased with age. High levels of IgG and IgG subclasses to all tested antigens except for 
GLURP R2 were associated with the intensity of malaria transmission. IgG to MSP3, MSP2b, GLURP R2 and GLURP R0 
were associated with low incidence of malaria. All IgG subclasses were associated with low incidence of P. falciparum 
malaria, but these associations were stronger for cytophilic IgGs.
Conclusions: On the basis of the data presented in this study, we conclude that the induction of humoral immune 
response to tested malaria antigens is related to age, transmission season level and incidence of clinical malaria.
Keywords: P. falciparum infection, Malaria transmission sessions, Age, Antigens
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Background
Children and pregnant women in sub-Saharan African 
are carrying the global P. falciparum malaria burden. 
It has been shown that there is a relationship between 
antibody production (levels, isotype, or function) and 
susceptibility to clinical malaria [1, 2]. Bouharoun-Tay-
oun and Druilhe found a significance difference in the 
distribution of immunoglobulin (Ig) subclasses between 
clinically protected and non-protected individuals. In 
their study, cytophilic isotypes (IgG1 and IgG3) are being 
reported to be dominant in protected individuals com-
pared to non-protected individual [3]. Similar findings 
were observed also for MSP2, MSP3 and GLURP where 
cytophilic antibodies were predominant in protected 
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individuals, while non cytophilic antibodies were pre-
dominant in non protected individuals [4–7].
There are several merozoite surface proteins with no 
specific function, including MSP2; MSP3 and GLURP 
[8]. Many of these antigens have been evaluated or devel-
oped as potential vaccine antigens [9]. Immuno-epide-
miological studies have shown that IgG to these antigens 
is associated with lower parasite density [10, 11] and 
the absence of disease [12] in children living in West-
Africa, and that levels of IgG responses to these antigens 
increased quickly with age and with level of exposure [6, 
13, 14].
MSP3 and GLURP have been tested in malaria vaccine 
antigens that have already undergone phase 1 trials. The 
efficacies of these malaria vaccines will be tested in phase 
II and III vaccine trials in Africa. For the purpose of the 
evaluation of the efficacy of these planned vaccine trials, 
it is important to investigate the induction of humoral 
immune response in protection against these vaccines 
antigens. However, the epidemiological evidence of the 
protective effect of naturally acquired anti-merozoite 
responses is not specifique. There could be many reasons 
for these inconsistencies. In malaria endemic areas the 
rate at which natural immunity develops is dependent on 
age, intensity and stability of exposure to P. falciparum, 
endemicity of malaria and clinical incidence [15, 16]. This 
study was conducted to evaluate the role of age, malaria 
transmission intensity and incidence of clinical malaria 
in the induction of protective humoral immune response 
against malaria vaccine candidates prior to clinical trials 
in children living in Burkina Faso.
Methods
Study area
The study was conducted in four villages randomly 
selected out of the 74 villages of the Saponé Health 
District (SHD). The SHD is located at the center of 
Burkina Faso at 50  km south-west of Ouagadougou. 
In SHD, the climate is characteristic of the Suda-
nese savannah with two seasons: a rainy season from 
June to October and a dry season from November to 
May where the malaria transmission is nearly absent. 
Malaria is endemic and its transmission in these areas 
is very high during the rainy season. P. falciparum is 
the deadliest specie that causes more than 95% of 
infections [17]. The principal vectors are An. gambiae, 
and An. funestus. From February to May, the number 
of infectious bites per person per night (Entomological 
Inoculation Rate (EIR)) was negligible. However, the 
EIR increased from June to September and decreased 
from September to November and remained low until 
the next rainy season [6, 17].
Study population
Study population was children from 6 months to 5 years 
fulfilling the following inclusion and exclusion criteria.
Inclusion criteria were (i) written/thumb printed 
informed consent obtained from the parent or legal 
guardian of each child enrolled to the study; (ii) perma-
nent resident in the study area for at least 3 months prior 
to enrollment and expected to remain at least for the all 
the period of longitudinal follow up; (iii) aged between 
6 months to 5 years.
Exclusion criteria were (i) major congenital defect or 
any chronic disease (including immune, cardiovascular, 
hepatic, HIV and renal) diagnosed by a physician/nurse 
based on medical history and physical examination; (ii) 
anemia defined as hemoglobin value less than 6 g/dl and 
(iii) any other circumstances and condition suspected by 
the physician to be the risk for the child health.
Only children fulfilling study inclusion criteria and 
attending both cross-sectional surveys were enrolled to 
the study. Data obtained by cross-sectional survey was 
used to reach study objectives. Children were enrolled 
for the assessment of malaria infection and immuno-
logical endpoints in relation to protection against clinical 
malaria, age and malaria transmission level.
Sample collection
Two cross-sectional surveys were carried out during low 
(January 2007) and high (September 2007) malaria trans-
missions seasons. During each cross-sectional survey, 
5 ml of venous blood in a tube containing EDTA was col-
lected from each child for a complete blood count. The 
remaining blood was centrifuged and aliquots of plasma 
were created and stored at −20  °C for immunological 
analysis. Thick and thin blood films were prepared from 
finger prick for microscopy diagnosis of malaria. Axillary 
temperature was measured at once. Children with fever, 
defined as axillary temperature ≥37.5  °C or history of 
fever reported within the last 24  h, had a malaria rapid 
diagnostic test (RDT) performed. A child with a positive 
test result was referred to the nearest health center for 
appropriate treatment of malaria which was given free of 
charge.
A longitudinal survey with active case detection of 
malaria episodes was conducted starting from the begin-
ning of the first cross-sectional survey. Twice weekly, 
each child was monitored clinically by a study nurse 
who resided in the village. During each visit, informa-
tion regarding health status was recorded and axillary 
temperature was measured as described previously. If 
the child had fever or history of fever reported within the 
last 24  h, a RDT was performed. In addition, thick and 
thin blood films were prepared and sent to the Centre 
National de Récherche et Formation sur le Paludisme 
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(CNRFP) laboratory for the determination of parasite 
density by using light microscopy. Patients with positive 
RDTs were referred at once to the nearest health care 
center for free treatment.
Malaria infection diagnosis
Plasmodium falciparum parasite is identified by examin-
ing thick and thin blood films. Each slide was air-dried 
and stained with 5% Giemsa to give a parasites a distinc-
tive appearance and was read by two different labora-
tory technicians. A slide was declared negative only after 
reading against 2000 white blood cells without observa-
tion of a malaria parasite. For blood smears collected 
during the cross-sectional survey, the number of para-
sites per microliter of blood was calculated according to 
the number of white blood cells obtained from a com-
pleted blood count; however, parasite densities for slides 
collected during the longitudinal survey were calculated 
assuming an average of 8000 white blood cells/µL of 
blood. In case of difference over the presence or absence 
of malaria parasites between different readers, or if para-
site density estimates differed by more than 30%, the slide 
was read one again by a third laboratory technician. The 
arithmetic mean of the two final readings was used as 
the final parasite density. If there was no agreement after 
the third reading, the arithmetic mean of the two most 
closed results was considered.
Immunological analysis
IgG and IgG subclass levels to merozoite surface anti-
gens MSP3, MSP2a, MSP2b, GLURP R0 and GLURP 
R2 (Table 1) were measured according to Afro Immuno 
Assay 2 (AIA2), standard operating procedure (SOP 
Number: AIA-001-02) [6, 14]. In brief, microtiter 
plates (Maxisorp Nunc –F 96 442404, Denmark) were 
coated with the appropriate antigens at 0.5  µg/ml and 
were incubated at 4 °C overnight. The plates were then; 
blocked with PBS Tween 20 (PBS with 5% milk powder, 
0.1% Tween-20) for 1 h. Plasma samples diluted 1:200 in 
serum dilution buffer (PBS with 2.5% milk powder, 0.1% 
Tween-20 and 0.02% Na-azide) were added in duplicate 
and incubated at room temperature for 2  h. Plate were 
washed four times between each step with washing 
buffer (PBS with 0.1% Tween-20 and 0.5 M NaCl). 50 μL 
per well of respective conjugated anti-human antibod-
ies were added. Antibodies used were peroxidase-con-
jugated goat anti-human IgG (γ) (H10007) (Invitrogen 
Corporation, CA, USA) (1:80,000) and the IgG sub-
classes antibodies (The Binding Site Group Ltd, UK): 
peroxidase-conjugated sheep anti-human IgG1 (AP006) 
(1:5000), peroxidase-conjugated sheep anti-human 
IgG2 (AP007) (1:2000), peroxidase-conjugated sheep 
anti-human IgG3 (AP008) (1:10,000) and peroxidase-
conjugated sheep anti-human IgG4 (AP009) (1:1000), 
all diluted in dilution buffer (0.1% Tween20 + 2.5% milk 
powder in PBS) and incubated for 1 h at room temper-
ature. After washing, the plates were developed with 
TMB (3,3′,5,5′-Tetramethylbenzidine) from Taastrup, 
Denmark (Kem-En-Tec Diagnosis A/S, Taastrup, Den-
mark) substrate and reactions stopped after 30  min by 
adding 50 µL of 0.2 M of sulfuric acid per well. Antibody 
levels, measured as optical density (OD) were deter-
mined at 450  nm with a reference at 630  nm, using a 
Biotek ELx808 microplate reader (Winooski, Vermont 
05404-0998 USA). The OD values of the test samples 
were converted into Arbitrary Units (AU) ADAMSEL 
b040, Ed Remark© 2009) by means of interpolation 
from a standard curve on each plate, obtained by using 
12 serial dilutions of a pool of positive hyperimmune 
sera (from CNRFP site). Positive control plasmas were 
obtained from positive Burkinabè adults over 20  years 
old, living in malaria hyper-endemic areas and nega-
tive controls were Danish (never exposed to malaria) 
plasma samples from Statens Serum Institute (Copenha-
gen, Denmark). Samples were re-tested if the coefficient 
of variation between duplicate absorbance values were 
higher than 15% and plates were also re-tested if the R2 
value of the standard curve was less than 97%. A mean 
low cut concentration were generated for all the analysis 
at 0.0028 AU.
Table 1 Characteristics of antigens used [8, 14, 19, 20]
Merozoite surface antigens
Antigen Synthesis stage Allelic type Polypeptides
MSP3 Merozoite surface
MSP2 Merozoite surface A 1–184 of strain CH150/9
B 22–247 of strain  Dd2
GLURP All stages of parasite R0 N-terminal non repetitive region  GLURP94–489
R2 C-terminal repetitive region  GLURP705–1178
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Data analysis
Data was performed using EPI info version 6.0. Data gen-
erated from assays in the form of ELISA OD values were 
entered into Microsoft Excel worksheets. SAS software 
Version 9.2 was used to perform analyses.
Incidence rates of malaria which included var-
ied thresholds of parasitemia (parasitemia  >  0, para-
sitemia ≥  2500, and parasitemia ≥  5000 asexual forms/
µL of blood) and axillary temperature ≥37.5  °C or his-
tory of fever within 24 h were calculated for the follow-
ing time periods: date of 1st cross sectional survey to date 
of 2nd cross sectional survey. Malaria episodes occurring 
within 28  days of a previous episode were not treated 
as incident episodes. When calculating person time in 
analyses of multiple malaria episodes, 28  days follow-
ing a new episode was subtracted from total time at risk. 
This was done to ensure that the infection causing the 
episode was recorded and subsequent episodes within 
the 28-day window were not counted. Overall incidence 
of malaria was calculated using the number of malaria 
events divided by time at risk. Geometric means for 
antigens were estimated using  log2 transformed values. 
The Wilcoxon signed-rank sum test was used to com-
pare geometric mean parasite densities across transmis-
sion seasons. Age adjusted incidence rate ratios against 




We performed immunological analysis of samples from 
325 children under 5 years old (mean age 2.71 years and 
the sex ratio M/F 1.12). Participants were followed up 
from February 2007 (low malaria transmission season) to 
December 2007 (peak of high malaria transmission sea-
son) to assess malaria clinical episodes and incidence.
As shown in Table  2, the prevalence of P. falciparum 
infection during low and high transmission seasons was 
59.69 and 50.76%, respectively. By contrast, the mean 
parasite density was lower during low malaria trans-
mission season compared to high transmission sea-
son; 2627  parasites/µL versus 6042  parasites/µL. Using 
increasingly stringent definitions of malaria by increasing 
the parasitemia threshold, during each of low and high 
transmission seasons, the incidence of malaria decreased. 
However, regardless of the clinical malaria definition, the 
incidence rates were always higher during high malaria 
transmission season.
Relationship between IgG levels and age
Children were categorized into five age groups to assess 
the age-dependent response of IgG to the tested antigens 
(MSP3, MSP2a, MSP2b, GLURP R0 and GLURP R2). 
In our study, older children had higher IgG responses 
than younger children for all tested antigens. Results are 
shown in Fig. 1. The difference was statistically different 
or borderline between the defined age groups in both 
transmission seasons: MSP3 (p < 0.0001 and p = 0.0069), 
MSP2a (p < 0.0001 and p = 0.0037), MSP2b (p < 0.0001 
and p < 0.0001), GLURP R0 (p < 0.0001 and p = 0.0508) 
and GLURP R2 (p < 0.0001 and p = 0.0010) respectively 
during low and high malaria transmission seasons.
Relationship between antibody levels and malaria 
transmission seasons
Levels of specific IgG and IgG subclasses antibodies 
in 325 children were compared between low and high 
malaria transmission seasons (Table 3). Overall IgG lev-
els to all antigens except for GLURP R2 were significantly 
higher during high malaria transmission season com-
pared to the measurement done during low transmission 
season, MSP3 (p < 0.001), MSP2a (p < 0.001) and GLURP 
R0 (p  <  0.001). The reverse effect was observed with 
GLURP R2 for which, the level of specific IgG was higher 
during low malaria transmission season (p = 0.0372).
IgG isotype levels were always higher in children during 
high malaria transmission period compared to low trans-
mission period but the difference were not significant for 
Table 2 Study population characteristics
Characteristics Number of children Low malaria transmission season High malaria transmission season
Baseline P. falciparum
 Negative 325 126 (43.3%) 160 (49.2%)
 Positive 325 194 (59.7%) 165 (50.8%)
Geometric means of parasites density/μL 325 2627 6042
Incidence of malaria (95% CI)
 >0 325 2.4 (2.2, 2.6) 2.9 (2.6, 3.3)
 ≥2500 325 1.7 (1.5, 1.9) 2.3 (2.0, 2.6)
 ≥5000 325 1.5 (1.3, 1.7) 2.0 (1.8, 2.3)
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IgG2 to MSP3 (p = 0.0738), IgG4 to MSP2a, IgG2, IgG3 
and IgG4 to MSP2b (p  =  0.10, p  =  0.39 and p  =  0.35 
respectively) and IgG1 to GLURP R0 (p = 0.2085).
Effect of clinical malaria incidence on antibody levels
Clinical malaria incidence rates was performed as pre-
viously described [6, 14, 17] (Tables 4, 5, 6). In a 1-year 
follow-up, it appears that IgG responses to GLURP R0 
and R2 were statistically associated with reduced risk of 
clinical malaria when adjusted for age. Higher levels of 
IgG to MSP2b were associated with a low risk of clinical 
malaria, the parasite threshold were brought to 2500 and 
5000 asexual stages/µL of blood (2500: p  =  0.03; 5000: 
p = 0.02). There was no evidence of such associations for 
total IgG to MSP3 and MSP2a (Table 4).
Among the four IgG isotypes, the two cytophilic classes 
(IgG1 and IgG3) were most associated with decreased 
malaria incidence. Association was strongest for IgG1 
to MSP3 (p =  0.01641; p =  0.01906 and p =  0.03405), 
GLURP R0 (p = 0.00019; p = 0.00002 and p = 0.00002) 
and GLURP R2 (p = 0.00087; p = 0.00074, p = 0.00096) 
respectively for parasitemia threshold >0 parasites; 
parasitemia threshold >2500 parasites and parasitemia 
threshold >5000 parasites (Table  5). There was also a 
significant association for IgG3 to MSP3 (p  =  0.02474, 
p = 0.00439; p = 0.00347) and GLURP R2 (p = 0.00066, 
p = 0.00003 and p = 0.00003).
When IgG2 and IgG4 were considered, there was no 
evidence of an association with malaria incidence for 
parasitemia >0, there was a moderate association, with 
borderline statistical significance of IgG4 to GLURP R2, 
(p  =  0.01839 (Table  6). With parasitemia thresholds of 
>2500 parasites and >5000, the associations were signifi-
cant for IgG2 to MSP2b (p = 0.00191 and p = 0.00172) 
and GLURP R2 (p = 0.01302 and p = 0.03444) and IgG4 
(p = 0.02417 and p = 0.02739); MSP2b (p = 0.03784 and 
p = 0.015) and GLURP R2 (p = 0.00056 and p = 0.00061) 
respectively for parasitemia more than 2500 parasite and 
5000 parasites.
Discussion
This study aimed was to continuously support malaria 
vaccine development based on specific P. falciparum 
asexual stage antigens. A distinguishing characteristic 
of our study is the combination of the quantification of 
IgG and IgG subclasses to P. falciparum antigens (MSP3, 
MSP2a, MSP2b, GLURP R0 and GLURP R2) using stand-
ardized methods with age and malaria transmission sea-
son as done in previous studies [6, 14, 17]. In addition, a 
longitudinal survey with active case detection of malaria 
Fig. 1 IgG level in children during both malaria transmission seasons by age groups: MSP2b, Merozoite Surface Protein 2b; GLURP R2, Glutamate 
Rich Protein R2; MSP2a, Merozoite Surface Protein 2a; GLURP R0, Glutamate Rich Protein R0; MSP3, Merozoite Surface Protein 3
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episodes conducted over 1  year allowed the evaluation 
of the parasitological status and the incidence of clinical 
malaria.
Our data showed that P. falciparum infection preva-
lence was high in low transmission season compared 
to high transmission season. This finding is surpris-
ing because most malariometric parameters have been 
reported to be highest during malaria high transmission 
seasons in seasonal and stable malaria transmission areas. 
However in this study there was biweekly active follow-
up, where children were treated with artemisinin com-
bination therapy (ACT) when (a) axillary temperature 
was ≥37.5 °C and (b) there was reported history of fever 
within last 24 h, with a positive rapid malaria diagnosis 
Table 3 IgG and IgG subclass levels in children during both periods of the malaria transmission seasons
*  p ≤ 0.05 was considered as statistically significant
Antigen Isotype N Low transmission season High transmission season p*
Geometric mean (95% CI) Geometric mean (95% CI)
MSP3 IgG 325 2.55 (2.12, 3.08) 7.29 (6.12, 8.67) <.0001
IgG1 325 4.35 (3.85, 4.92) 9.41 (8.47, 10.44) <.0001
IgG2 325 4.95 (4.48, 5.47) 4.96 (4.53, 5.42) 0.065
IgG3 325 1.33 (1.08, 1.63) 2.89 (2.42, 3.45) <.0001
IgG4 325 3.15 (2.88, 3.45) 2.95 (2.64, 3.29) <.0001
MSP2a IgG 325 14.82 (11.92, 18.43) 33.21 (27.79, 39.67) <.0001
IgG1 325 3.60 (3.11, 4.16) 5.73 (4.92, 6.67) 0.0012
IgG2 325 3.38 (3.08, 3.71) 3.95 (3.46, 4.51) <.0001
IgG3 325 12.43 (10.22, 15.11) 15.04 (12.48, 18.13) 0.0147
IgG4 325 2.52 (2.08, 3.05) 2.64 (2.21, 3.15) 0.0539
MSP2b IgG 325 24.50 (19.63, 30.57) 37.01 (31.38, 43.66) 0.3356
IgG1 325 5.66 (4.89, 6.55) 13.15 (11.58, 14.93) <.0001
IgG2 325 4.29 (3.94, 4.66) 3.62 (3.12, 4.21) 0.1138
IgG3 325 11.90 (9.56, 14.81) 13.73 (11.19, 16.85) 0.4537
IgG4 325 1.65 (1.31, 2.08) 1.99 (1.64, 2.42) 0.3316
GLURP-R0 IgG 325 3.65 (3.03, 4.41) 6.31 (5.08, 7.84) <.0001
IgG1 325 3.76 (3.24, 4.35) 3.38 (2.87, 3.98) 0.2451
IgG2 325 1.13 (1.01, 1.26) 4.45 (3.93, 5.04) <.0001
IgG3 325 1.46 (1.24, 1.71) 0.97 (0.82, 1.14) <.0001
IgG4 325 1.62 (1.42, 1.85) 0.34 (0.30, 0.38) <.0001
GLURP-R2 IgG 325 33.45 (27.73, 40.36) 31.60 (26.44, 37.77) 0.0372
IgG1 325 17.59 (14.02, 22.06) 41.35 (34.08, 50.17) <.0001
IgG2 325 7.42 (5.84, 9.43) 30.11 (26.56, 34.14) <.0001
IgG3 325 16.77 (13.17, 21.36) 12.87 (10.02, 16.52) 0.0001
IgG4 325 6.87 (6.01, 7.85) 5.07 (4.40, 5.85) <.0001
Table 4 Age adjusted incidence rate ratios (IRR) (95% CI) for  the association between  total IgG from  low to  the end 
at high malaria transmission season
*  p ≤ 0.05 was considered as statistically significant
Antigen Parasitemia > 0 Parasitemia > 2500 Parasitemia > 5000
Age adjusted (95% CI) p Age adjusted IRR (95% CI) p Age adjusted IRR (95% CI) p*
MSP3 0.98 (0.947, 1.008) 0.14 0.97 (0.934, 1.012) 0.2 0.97 (0.932, 1.013) 0.17
MSP2a 0.99 (0.968, 1.021) 0.66 0.98 (0.949, 1.016) 0.29 0.98 (0.944, 1.012) 0.20
MSP2b 0.99 (0.963, 1.019) 0.52 0.96 (0.928, 0.996) 0.031 0.96 (0.924, 0.994) 0.02
GLURP-R0 0.96 (0.927, 0.987) 0.006 0.94 (0.902, 0.977) 0.002 0.93 (0.891, 0.969 0.0006
GLURP-R2 0.94 (0.907, 0.968) 0.0001 0.91 (0.875, 0.952) 0.00002 0.91 (0.873, 0.953) 0.00003
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test. Repeated treatment with ACT during these malaria 
illnesses might prevent malaria infection throughout the 
period of greatest malarial risk. As expected, the asexual 
parasite load and clinical malaria incidence regardless of 
parasite density thresholds peaked during the malaria 
intense transmission period. As shown in previous stud-
ies, these patterns are characteristic of our study area 
[18–20].
As shown in this paper, recent studies with blood-
stage antigens carried out in areas where malaria is 
endemic have reported increasing antibody (IgG and 
IgG isotypes) levels with age [6, 14]. This is consist-
ent with the hypothesis that immunity to malaria is 
largely built up throughout long-term exposure to 
malaria parasites [21]. Increasing IgG levels with age 
may reflect greater cumulative exposure of older 
children to malaria parasites, but may also be due to 
older children having a more fully developed acquired 
immune system [22].
Seasonal variation of IgG antibody responses to malaria 
parasite antigens has already been assessed in malaria 
endemic settings, where the responses were influenced 
by seasonal variation [17, 23]. In our current study, the 
same trend was observed with the level of antibodies 
against asexual blood antigens (MSP3, MSP2a, MSP2b, 
and GLURP R0) suggesting that the acquisition of the 
immunity against malaria is dependent on the intensity 
of malaria transmission. Surprisingly the reverse obser-
vation was made for IgG to GLURP R2, showing slightly 
higher level of antibodies during low transmission com-
pared with the high transmission season. As previously 
reported by Nebie and colleagues, it has been suggested 
that above certain level of transmission, antigen load 
may induce a disturbance of humoral response leading 
Table 5 Age-adjusted Incidence rate ratios for cytophilic IgG with malaria incidence from low to the end of high trans-
mission season
*  p ≤ 0.05 was considered as statistically significant
Antibodies/antigen Parasitemia > 0 Parasitemia > 2500 Parasitemia > 5000
Age adjusted (95% CI) p Age adjusted (95% CI) p Age adjusted (95% CI) p*
IgG1 MSP3 0.94 (0.897, 0.989) 0.016 0.93 (0.872, 0.988) 0.02 0.93 (0.874, 0.995) 0.034
MSP2a 0.99 (0.956, 1.031) 0.7 0.98 (0.936, 1.029) 0.44 0.97 (0.919, 1.014) 0.16
MSP2b 1.00 (0.959, 1.037) 0.90 0.98 (0.936, 1.033) 0.5 0.98 (0.932, 1.032) 0.45
GLURP-R0 0.93 (0.892, 0.965) 0.0002 0.90 (0.851, 0.942) 0.00002 0.89 (0.845, 0.939) 0.00002
GLURP-R2 0.96 (0.932, 0.982) 0.001 0.94 (0.914, 0.976) 0.0007 0.94 (0.912, 0.977) 0.001
IgG3 MSP3 0.97 (0.940, 0.996) 0.024 0.95 (0.913, 0.983) 0.004 0.94 (0.908, 0.981) 0.003
MSP2a 0.99 (0.960, 1.020) 0.49 0.97 (0.934, 1.008) 0.12 0.97 (0.929, 1.005) 0.091
MSP2b 0.98 (0.948, 1.005) 0.1 0.95 (0.911, 0.981) 0.003 0.94 (0.903, 0.975) 0.0011
GLURP-R0 0.98 (0.942, 1.010) 0.16 0.96 (0.918, 1.003) 0.068 0.96 (0.913, 1.001) 0.056
GLURP-R2 0.96 (0.936, 0.982) 0.0007 0.94 (0.907, 0.966) 0.00003 0.93 (0.903, 0.964) 0.00003
Table 6 Age-adjusted Incidence rate ratios for  non cytophilic IgG with  malaria incidence from  low to  the end of  high 
malaria transmission season
*  p ≤ 0.05 was considered as statistically significant
Antibodies/antigen Parasitemia > 0 Parasitemia > 2500 Parasitemia > 5000
Age adjusted (95% CI) p Age adjusted (95% CI) p Age adjusted (95% CI) p*
IgG2 MSP3 1.02 (0.963, 1.080) 0.50 1.04 (0.964, 1.113) 0.34 1.04 (0.965, 1.121) 0.3
MSP2a 0.98 (0.923, 1.042) 0.53 0.96 (0.889, 1.033) 0.27 0.95 (0.879, 1.027) 0.2
MSP2b 0.94 (0.877, 1.011) 0.095 0.87 (0.798, 0.950) 0.002 0.87 (0.791, 0.947) 0.002
GLURP-R0 1.00 (0.954, 1.054) 0.92 0.99 (0.927, 1.054) 0.72 1.00 (0.935, 1.066) 0.958
GLURP-R2 0.98 (0.959, 1.008) 0.17 0.96 (0.931, 0.992) 0.013 0.97 (0.934, 0.997) 0.034
IgG4 MSP3 0.95 (0.886, 1.014) 0.12 0.90 (0.824, 0.987) 0.024 0.90 (0.819, 0.988) 0.03
MSP2a 0.98 (0.950, 1.011) 0.21 0.97 (0.935, 1.012) 0.16 0.97 (0.931, 1.011) 0.15
MSP2b 0.98 (0.957, 1.007) 0.16 0.97 (0.934, 0.998) 0.038 0.96 (0.925, 0.992) 0.015
GLURP-R0 0.98 (0.939, 1.023) 0.35 0.99 (0.941, 1.046) 0.78 0.97 (0.922, 1.030) 0.37
GLURP-R2 0.94 (0.899, 0.990) 0.02 0.89 (0.826, 0.949) 0.0006 0.88 (0.818, 0.947) 0.0006
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to lower antibody levels, which may explain this find-
ing [17, 23]. Some evidence in support of this hypoth-
esis was found in Madagascar, where higher quantities 
of circulating stable antigens were reported to down-
regulate antibody responses to P. falciparum. However 
we cannot exclude that this observation may also be due 
to a random variation. As shown in other studies, cyt-
ophilic antibody levels to the five antigens tested in this 
study were higher than non-cytophilic ones independ-
ent of the malaria transmission season, emphasizing 
their importance in anti-malaria immunity [3, 7, 13, 21, 
22, 24–26]. Many previous studies have shown that the 
B-cell epitopes of MSP3 and GLURP are targeted by IgG1 
and IgG3, and, in conjunction with blood mononuclear 
cells via their FcγRII receptors, trigger the release of kill-
ing factors, such as tumor necrosis factor [1, 13, 27, 28].
Previous studies using human sera from people liv-
ing in malaria endemic areas have found evidence of an 
association between the levels of total IgG to MSP3 and 
GLURP and a reduced subsequent risk of clinical malaria 
[29–31]. For GLURP antigens, we found that there is an 
association between total IgG antibodies and a lower risk 
of clinical malaria in the majority of the study population. 
While, we observed the controversial situation for MSP3. 
Our data show that GLURP R0 and R2-specific IgG are 
correlated with a reduced risk of P. falciparum clinical 
malaria, but we find no evidence for associations with 
MSP3, MSP2a and MSP2 for malaria episodes defined by 
a parasitemia threshold >0. For malaria definitions with 
parasitemia thresholds >2500 and >5000, in addition 
to GLURP R0 and GLURP R2, we observed that IgG to 
MSP2b was correlated with reduced risk of P. falciparum 
clinical malaria, suggesting that by increasing the sensi-
tivity of our clinical malaria case definition, IgG to these 
three antigens provide strong evidence of associations 
with protection against malaria. Previous studies carried 
out in the same area found that there is an association 
between the antibody responses to MSP3 and GLURP 
long synthetic peptides at the beginning of the malaria 
high transmission season and the reduced risk of clini-
cal malaria [31], although two recent studies in Ghana 
and Senegal could not confirm those findings [14, 32]. 
The reasons for these discordant observations may be 
due to the variations in the technical procedures used for 
ELISA, the study design, the genetic background of study 
population as well as the pattern of malaria transmission. 
The major role may be played by malaria transmission 
level through the variations in the degree of exposure to 
particular antigens have probably the strongest influence 
on outcomes [21].
IgG1 responses to MSP3, GLURP R0 and GLURP R2 
were associated with a reduced risk of malaria when the 
analysis is adjusted with age for all parasitemia thresholds 
defined. The same observation was seen for IgG3 to 
MSP3, and GLURP R2, with significant associations with 
IgG3 to MSP2b also observed for the >2500 and >5000 
thresholds. These data suggest a role for cytophilic IgGs 
in protection against clinical malaria. IgG2 and IgG4 
to MSP3 and GLURP R2 and IgG4 to MSP2b were also 
associated with a reduced risk of malaria. These data 
confirm those previously reported suggesting that IgG2, 
which preferentially binds the Fcγ receptor IIa 131H 
allele, is associated with protection against severe malaria 
[33–37]. However another study has shown that IgG2 is 
associated with susceptibility to malaria [38]. In contrast 
to four other antigens, no association was found for IgG 
subclass responses to MSP2a. It clearly appears that the 
pattern of the responses induced by this antigen is differ-
ent from MSP3, MSP2b, GLURP R0 and GLURP R2. It 
is unknown whether the differences in MSP2a antibody 
reactivity observed in this study are related to its struc-
tural conformation with the tandem repeat sequences, 
or the polymorphic nature of some of these repeat 
sequences.
Conclusion
On the basis of the data presented in this study, we con-
clude that natural acquired immunity to malaria anti-
gens is related to age and transmission season levels 
in children less than 5 years. All the tested antigens are 
inducing antibody responses, which are associated with 
clinical malaria protection. Notwithstanding the fac-
tors that may affect the pattern of the immunological 
responses induced by these malaria vaccine candidates, 
the data presented in this paper are strongly in support 
of the inclusion of these antigens in malaria vaccine 
formulations.
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